NEW YORK, March  23, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and

RPRX

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma strengthens AI capabilities with new leadership appointment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, March  23, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Royalty Pharma has appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026. His expertise will bolster the firm&#039;s investment evaluation and operational efficiency, likely enhancing competitive positioning in the biopharmaceutical market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lucas Glass appointed Head of AI at Royalty Pharma effective April 2026.</li><li>Focus on advanced analytics and AI for improved decision-making.</li><li>Glass brings over ten years of AI and data solutions experience.</li><li>Royalty Pharma emphasizes commitment to cutting-edge technology investments.</li><li>The company has royalties on over 35 commercial products.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>IQVIA (IQV)</strong>: Lucas Glass&#039;s experience at IQVIA may enhance RPRX&#039;s technology strategies.</li><li><strong>Vertex Pharmaceuticals (VRTX)</strong>: RPRX holds royalties on Vertex&#039;s leading therapies like Trikafta.</li><li><strong>Biogen (BIIB)</strong>: RPRX collects royalties from Biogen’s products like Tysabri.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits under &#039;Corporate Developments&#039; due to the strategic hire aimed at improving decision-making processes at Royalty Pharma. The investment in AI is indicative of a forward-looking strategy aimed at sustaining competitive advantage in a dynamic market.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lucas Glass&#039;s role signifies a strategic shift towards advanced technology at RPRX.</li><li>Improved decision-making could lead to enhanced royalty acquisitions for RPRX.</li><li>Investors might respond positively to the focus on competitive advantage through AI.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Lucas Glass starts as Head of AI in April 2026.</li><li>Royalty Pharma has over 35 commercial product royalties.</li><li>Company aims to enhance decisions with AI and advanced analytics.</li><li>Pablo Legorreta leads Royalty Pharma as CEO.</li><li>Glass previously worked at IQVIA focusing on technology solutions.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying RPRX, as AI integration may drive profitable growth in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>NEW YORK, March  23, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RPRX">RPRX</a>) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma.</p>  <p>"Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Lucas brings more than a decade of experience building enterprise-scale AI and data solutions in life sciences and his work will enhance Royalty Pharma's competitive advantage through more informed decision-making and improved efficiency across the firm."</p>  <p>Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University.</p>  <p><strong>About Royalty Pharma </strong></p>  <p>Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Astellas and Pfizer's Xtandi, Johnson &amp; Johnson's Tremfya, AbbVie and Johnson &amp; Johnson's Imbruvica, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, among others, and 19 development-stage product candidates. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=uO6Y5iA1zyDtB2nf_VzF7ypCbLZ_RdO4_EhgRfAt2Ap6T_grP9iO3ezCjNpi8WeSrIfvqPgqzrU-JxY8R7f9tdEMuqFNEwgnl2S9sIMhqTk=" rel="nofollow" target="_blank">www.royaltypharma.com</a>.     </p>  <p><strong>Forward-Looking Statements</strong></p>  <p>The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.</p>  <p>This document contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities, market growth and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.</p>  <p>Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.</p>  <p>For further information, please reference Royalty Pharma's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=2yxqFCiYhx9y1ejNygQ_1XgXr-6AtyZyP-RdGq5UcNBwFopzdKGf6asumxsb-J-FsPqOAQgIy6F1NzEJEm6Kxw==" rel="nofollow" target="_blank">www.sec.gov</a>.</p>  <p><strong>Royalty Pharma Investor Relations and Communications</strong></p>  <p align="justify">+1 (212) 883-6772<br></br><a href="https://www.globenewswire.com/Tracker?data=mPuQdMOAXREdfyWUjM2oY3vKU1cEXML1l1zPEfzf_jNsmMQrdP5SbZGtRruXTo9zMDCdJNcze07B4fPlsfqFm_SF1l_fujKt4vRB1fTCwtM=" rel="nofollow" target="_blank">ir@royaltypharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3NjUzNyM3NDk3OTI2IzUwMDEwNTI2NA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODI3YjJmZjUtNjU1MC00NWNlLThlZDgtMTUwNjgzMTY0ZGMwLTUwMDEwNTI2NC0yMDI2LTAzLTIzLWVu/tiny/Royalty-Pharma-plc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d605b3b0-7ba0-46e1-a2d4-439ca98694f8"><img src="https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg" border="0" width="150" height="9" alt="Primary Logo"></img></a></p>

Royalty Pharma has appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026. His expertise will bolster the firm's investment evaluation and operational efficiency, likely enhancing competitive positioning in the biopharmaceutical market.

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News